Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Damora Therapeutics, Inc.

Healthcare US DMRA

25.47USD
4.24(19.97%)

Last update at 2026-06-22T17:45:00Z

Day Range

21.5125.26
LowHigh

52 Week Range

2.4538.33
LowHigh

Fundamentals

  • Previous Close 21.23
  • Market Cap1593.81M
  • Volume212506
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-36.54000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.98

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -209.78900M -21.39800M -38.34900M -61.62400M -51.75200M
Minority interest - - - - -
Net income -209.83900M -21.43900M -38.34900M -61.62400M -51.75200M
Selling general administrative 9.69M 10.50M 12.69M 13.00M 13.74M
Selling and marketing expenses - - - - -
Gross profit -0.03400M -0.18100M -0.83000M -0.49000M -0.44100M
Reconciled depreciation 0.03M 0.18M 0.83M 0.49M 0.44M
Ebit -210.87200M -16.89700M -36.45700M -61.20700M -52.22700M
Ebitda -210.83800M -16.71600M -35.62700M -60.71700M -51.78600M
Depreciation and amortization 0.03M 0.18M 0.83M 0.49M 0.44M
Non operating income net other - - - - -
Operating income -210.87200M -16.89700M -36.45700M -61.20700M -52.22700M
Other operating expenses 210.87M 16.90M 36.46M 61.21M 52.23M
Interest expense - - - - -
Tax provision 0.05M 0.04M 0.00000M - -
Interest income 1.17M 0.84M 1.69M 0.72M 0.16M
Net interest income 1.17M 0.84M 1.69M 0.72M 0.16M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M 0.04M - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 210.87M 16.72M 35.63M 60.72M 51.79M
Cost of revenue 0.03M 0.18M 0.83M 0.49M 0.44M
Total other income expense net 1.08M -4.50100M -1.89200M -0.41700M 0.47M
Discontinued operations - - - - -
Net income from continuing ops -209.83900M -21.43900M -38.34900M -61.62400M -51.75200M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 260.53M 17.13M 38.23M 73.19M 122.22M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.90M 1.78M 1.91M 2.31M 7.63M
Total liab 20.15M 2.66M 5.90M 11.44M 4.99M
Total stockholder equity 240.38M 14.47M 32.33M 61.75M 117.22M
Deferred long term liab - - - - -
Other current liab 19.61M 0.81M 3.94M 7.28M 2.61M
Common stock - - - - -
Capital stock 416.25M 1.36M 0.00000M 0.00000M 0.00000M
Retained earnings -487.36300M -277.52400M -256.08500M -217.73600M -156.11200M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 257.62M 14.18M 21.46M 32.79M 62.56M
Cash and equivalents - - - - -
Total current liabilities 20.07M 1.20M 5.83M 11.11M 4.54M
Current deferred revenue - - - - -
Net debt -257.55600M -12.74200M -21.21600M -31.98200M -61.71600M
Short term debt 0.01M 0.01M 0.18M 0.48M 0.40M
Short long term debt - - - - -
Short long term debt total 0.07M 1.43M 0.25M 0.80M 0.85M
Other stockholder equity 310.69M 291.90M 288.04M 279.73M 273.65M
Property plant equipment - - - - -
Total current assets 260.42M 16.84M 36.77M 63.91M 110.10M
Long term investments - - 0.00000M 5.83M 9.05M
Net tangible assets - - - - -
Short term investments - 0.00000M 11.69M 27.44M 37.63M
Net receivables 0.90M 0.88M 1.72M 1.38M 2.28M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.44M 0.38M 1.70M 3.35M 1.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.80M 0.10M 0.38M -0.24400M -0.32000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.16M 1.13M 2.28M 2.03M
Deferred long term asset charges - - - - -
Non current assets total 0.10M 0.29M 1.45M 9.28M 12.11M
Capital lease obligations 0.07M 0.07M 0.25M 0.80M 0.85M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 11.65M 22.25M 12.58M -47.82500M
Change to liabilities - - - - -
Total cashflows from investing activities -17.37400M 11.65M 22.33M 12.38M -48.04800M
Net borrowings - - - - -
Total cash from financing activities 266.84M 0.00000M 2.88M 0.51M 0.00000M
Change to operating activities - - - - -
Net income -209.83900M -21.43900M -38.34900M -61.62400M -51.75200M
Change in cash 243.45M -7.29000M -11.32100M -29.77700M -101.01900M
Begin period cash flow 14.18M 21.46M 32.79M 62.56M 163.58M
End period cash flow 257.62M 14.18M 21.46M 32.79M 62.56M
Total cash from operating activities -6.72600M -18.62300M -36.91100M -42.93200M -52.30800M
Issuance of capital stock 266.81M 0.00000M 2.88M 0.51M 0.00000M
Depreciation 0.03M 0.18M 0.83M 0.49M 0.44M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 266.84M - - - -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.20M 0.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 18.36M -2.66700M -4.37000M 11.94M -6.62400M
Stock based compensation 1.00M 3.24M 5.43M 5.57M 4.48M
Other non cash items 183.72M 5.30M 4.98M 6.26M 5.63M
Free cash flow -6.72600M -18.62300M -36.91100M -43.12800M -52.53100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
DMRA
Damora Therapeutics, Inc.		 4.24 19.97% 25.47 - - - 163.79 0.46
NVO
Novo Nordisk A/S		 2.94 6.80% 46.12 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.54 2.78% 464.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -1.76 0.29% 608.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Damora Therapeutics, Inc.

Building 23, Waltham, MA, United States, 02453

Key Executives

Name Title Year Born
Ms. Lori C. Firmani Chief Financial Officer 1974
Mr. Garrett Winslow Esq. Senior VP, General Counsel & Corporate Secretary 1980
Ms. Jennifer A. Jarrett M.B.A. CEO, President & Director 1971
Mr. Ulf J. Nilsson Ph.D. Co-Founder NA
Dr. Hakon Leffler M.D., Ph.D. Co-Founder NA
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder NA
Mr. Sherwin Sattarzadeh Chief Operating Officer NA
Dr. Becker Hewes M.D. Chief Medical Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions